Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis

Exclusion Criteria

• •1. Participants with hypersensitivity to ganciclovir capsules and its excipients.
• •2. Have symptoms of viral infection, fever and other systemic symptoms in the past 2 weeks.
• •3. Pregnant or lactating women and participants who have pregnancy plan during the study period.
• •4. Participants with severe neutropenia (absolute neutrophil count less than 0.5\*10\^9/L) or severe thrombocytopenia (platelet count less than 2.5\*10\^10/L).
• •5. Comorbidities such as upper and lower respiratory tract infections, history of acute or chronic sinusitis, dry rhinitis, atrophic rhinitis, severe deviated septum and asthma.
• •6. Participants with other severe heart, lung, liver and kidney disease.
• •7. Participants who had received any live or attenuated vaccine within 4 weeks prior to baseline or intended to receive live or attenuated vaccine (or BCG treatment) during the study period or within 4 weeks after the last administration of the investigational drug product.
• •8. Participants with a history of HIV infection or who test positive for HIV serology.
• •9. Participants currently infected or chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV).
• •10. Participants with cirrhosis and/or chronic hepatitis.
• •11. Participants who have been diagnosed with active parasitic infections or are at high risk of developing such infections.。
• •12. Participants with a known or suspected history of immunosuppression, including a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumosporidiosis, aspergillosis). Or participants with what researchers believe to be unusually frequent, recurring, or prolonged infections.
• •13. Participants with a known history of malignancy within 5 years prior to screening.
• •14. Participants with severe co-morbidities that, in the opinion of the investigator, would adversely affect their participation in this study.
• •15. Participants with combined neurological or psychiatric disorders who are unable or reluctant to cooperate.
• •16. Participants with disabilities prescribed by law (blind, deaf, mute, mentally challenged, mentally handicapped, etc.).
• •17. Participants suspected or having a history of alcohol and drug abuse.
• •18. Other participants who have been involved in other clinical trials within 3 months before the screening.
• •19. The researchers consider it inappropriate to participate in this clinical trial.